Healthy Volunteers Clinical Trial
Official title:
Physiology of Volition Studied With Nerve Block
Verified date | January 4, 2012 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- The experience of volition that accompanies voluntary movement can be divided into the
sense of will, or deciding to move, and the sense of agency, or feeling that the movement
just made was self-generated. Very little is known regarding the neurological origin of this
sense of volition. Previous research has shown that a particular part of the brain, the
parietal lobe, is involved in our inner sense that we control the movements we make.
Researchers are interested in determining if this sense relies on sensory information from
moving fingers reaching the parietal lobe.
Objectives:
- To determine the brain regions responsible for the sense of volition and the associated
sense of agency.
Eligibility:
- Healthy right-handed individuals between 18 and 55 years of age.
Design:
- The study will involve a screening visit and two testing visits. The screening visit
will last 30 minutes to 1 hour, and the testing visits will each last 3 to 4 hours.
- Participants will be screened with a physical examination and medical history.
- At each testing visit, participants will have a brain magnetic resonance imaging (MRI)
scan, electroencephalography (EEG), and electromyography (EMG). The MRI scan and EEG
will be done during a movement task that involves the thumb, second finger, and fifth
finger of one hand. EMG will be used to monitor movements and muscle activity.
- During the second testing visit, participants will receive a nerve block using
anesthetic, followed by the MRI, EEG, EMG and movement task. The nerve block will
temporarily numb and prevent the movement of parts of the hand and fingers.
- After the MRI scan and EEG recording, participants will be asked to rate how much
control they felt they had over choosing whether to move, and how much control they felt
they had in actually making the movements.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 4, 2012 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
- INCLUSION CRITERIA: Healthy right-handed subjects ranging from 18 to 55 will be included. All subjects should have a valid Clinical Center Medical Record Number. EXCLUSION CRITERIA: 1. Healthy subjects younger than 18 years and older than 55 will be excluded. 2. Subjects with MRI findings consistent with organic brain lesions such as brain tumors, stroke, trauma or AVMs will be excluded. 3. Subjects with active significant medical or neurological disorders, or active Axis I psychiatric disorders, or requiring continuous treatment with drugs that affect the central nervous system will be excluded. 4. We will not include pregnant women because safety of high magnetic field to fetus is not established. 5. Subjects allergic to local anesthetics such as bupivacaine will be excluded. 6. Subjects unable to have an MRI due to claustrophobia or contraindications to MR scanning will be excluded. 7. Subjects who are left-handed will be excluded. 8. Subjects will be excluded who are taking anticoagulant or antiplatelet medications such as warfarin, heparin, clopidogrel, ticlopidine, or fondiparinux, or vitamin E in amounts greater than 1600 IU per day. 9. If subjects are taking daily aspirin therapy, this must be held for 7 days prior to the nerve block. If subjects are taking daily NSAIDs, these must be held for 12 hours prior to the nerve block. If these medications cannot be held for these periods, the subject will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Blakemore SJ, Oakley DA, Frith CD. Delusions of alien control in the normal brain. Neuropsychologia. 2003;41(8):1058-67. — View Citation
Deecke L, Kornhuber HH. An electrical sign of participation of the mesial 'supplementary' motor cortex in human voluntary finger movement. Brain Res. 1978 Dec 29;159(2):473-6. — View Citation
Libet B, Gleason CA, Wright EW, Pearl DK. Time of conscious intention to act in relation to onset of cerebral activity (readiness-potential). The unconscious initiation of a freely voluntary act. Brain. 1983 Sep;106 (Pt 3):623-42. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |